Sepsis News and Research

Latest Sepsis News and Research

Estradiol prevents vascular permeability following hemorrhagic shock: Study

A study published in the September 2010 issue of SHOCK by Dr. Ed W. Childs and colleagues at Scott & White Healthcare looks at how female versus male rats fared after suffering a trauma and subsequent hemorrhagic shock who were given Estradiol (estrogen). In the study, the Estradiol prevented vascular permeability following hemorrhagic shock.

2 Sep 2010

NSW bed sore death could have been prevented: Coroner

After the death of a severely disabled woman in New South Wales, the coroner has ruled that the death due to bed sores was avoidable and caregivers need more training to manage such cases. 26-year-old Kate Therese Bugmy died at Broken Hill Base Hospital in June 2007 as a result of sepsis from bed sores. She had severe cerebral palsy, epilepsy and an intellectual disability and weighed just 36 kilos when she died.

26 Aug 2010

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.

24 Aug 2010

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.

20 Aug 2010

Assessment of critical illness during Emergency Medical Services care

A prediction score that included such factors as age, blood pressure, heart and respiratory rate for patients who received out-of-hospital emergency care was associated with the development of critical illness during hospitalization such as severe sepsis, the need for mechanical ventilation or death, according to a study in the August 18 issue of JAMA.

19 Aug 2010

World MRSA Day kick-off event in Chicago on October 1, 2010

MRSA Survivors Network, the Chicago-based nonprofit organization, launches their second annual World MRSA Day kick-off event at Loyola University Chicago on October 1, 2010. The 2010 global theme for World MRSA Day is: 'The MRSA Epidemic – A Call to Action.' Other events are planned in the United States, U.K. and Canada throughout the month of October, World MRSA Awareness Month.

19 Aug 2010

Scientists find therapeutic potential of stem cells for acute lung injury

Researchers are reporting this week new study results they say provide further evidence of the therapeutic potential of stem cells derived from bone marrow for patients suffering from acute lung injury, one of the most common causes of respiratory failure in intensive care units.

12 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Health Affairs: Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality - This study examines differences in hospital mortality and cost between 2000 and 2004 for patients at 122 U.S. hospitals, with seven common medical diagnoses: acute myocardial infarction, chronic obstructive pulmonary disease, community-acquired pneumonia, congestive heart failure, cerebrovascular accident (also called ischemic stroke), sepsis, or urinary tract infection.

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Study analyzes prevalence of pediatric patient-safety events at hospitals

Hospital-acquired infections are the leading cause of potentially preventable mortality among pediatric patients, according to a study of pediatric patient-safety incidents issued today by HealthGrades, the leading independent health care ratings organization.

4 Aug 2010

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

2 Aug 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

People with schizophrenia are more likely than others to sustain medical injuries during non-psychiatric hospital stays, a large national study finds.These findings confirm that medical and surgical hospitalizations are an at-risk time for this group, and a national problem, said lead study author Elizabeth Khaykin, at the Department of Mental Health at Bloomberg Johns Hopkins School of Public Health.

23 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

Sepsis News and Research

Latest Sepsis News and Research

Estradiol prevents vascular permeability following hemorrhagic shock: Study

NSW bed sore death could have been prevented: Coroner

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

Tasigna receives approval for chronic myeloid leukemia in Canada

Assessment of critical illness during Emergency Medical Services care

World MRSA Day kick-off event in Chicago on October 1, 2010

Scientists find therapeutic potential of stem cells for acute lung injury

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

Targacept licenses Cornerstone technology for inflammatory disorders program

Study analyzes prevalence of pediatric patient-safety events at hospitals

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Sepsis News and Research

Latest Sepsis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in